Serum cytokeratin 19 fragment 21‐1 is a useful tumor marker for the assessment of extramammary Paget's disease. Issue 6 (2nd February 2017)

• Record Type: Journal Article
• Authors: Kato, Junji; Sumikawa, Yasuyuki; Hida, Tokimasa; Kamiya, Takafumi; Horimoto, Kohei; Kamiya, Shiori; Sato, Sayuri; Takahashi, Hitomi; Sawada, Masahide; Yamashita, Toshiharu
• Is Part Of: Journal of dermatology. Volume 44:Issue 6(2017)
• Page Start: 666
• Page End: 670
• Publication Date: 2017-02-02
• Subjects: cytokeratin 19 fragment 21‐1 -- cytokeratin 19 -- extramammary Paget's disease -- lymph node metastasis; Dermatology -- Periodicals; Dermatology -- Japan -- Periodicals; Skin -- Diseases -- Periodicals; 616.5005
• DOI: 10.1111/1346-8138.13760
• Languages: English
• ISSNs: 0385-2407

Abstract

Abstract: Cytokeratin 19 fragment 21‐1 (CYFRA 21‐1) has been used as a tumor marker for several malignancies. However, to date, no studies have assessed whether CYFRA 21‐1 could be a useful marker for extramammary Paget's disease (EMPD). The present study aimed to evaluate the significance of CYFRA 21‐1 as a serum tumor marker for EMPD progression. Concentrations of serum CYFRA 21‐1 and carcinoembryonic antigen (CEA) in 13 cases of EMPD were measured prior to undergoing treatment at Sapporo Medical University Hospital from January 2014 to May 2016. Four of the 13 patients had lymph node metastases at diagnosis, but none had distant metastases. Immunohistochemistry indicated that all 13 primary tumors and four metastatic tumors in lymph nodes were positive for cytokeratin 19. Although none of the 13 patients showed high serum CEA levels, six patients (46.2%) had elevated serum CYFRA 21‐1. Furthermore, CYFRA 21‐1 was reduced in association with post‐treatment tumor reduction in all six patients. Among these six patients, four developed recurrence and metastasis during the follow‐up period. CYFRA 21‐1 was re‐elevated in all four of these patients; however, serum CEA was elevated only in the patient with distant metastasis. These results suggest that CYFRA 21‐1 is more sensitive compared with CEA, and can be useful as a tumor marker for evaluating tumor progression and treatment efficacy in patients with EMPD.